FIELD: medicine; therapy.
SUBSTANCE: invention relates to medicine, namely to therapy; it can be used for the treatment of a disorder characterized by hypermethylation of POMC gene in a subject. An agonist of a melanocortin 4 receptor (hereinafter – MC4R), having the formula Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 (SEQ ID NO: 140), is administered as a drug at a daily dose from 0.1 mg to 10 mg.
EFFECT: method provides effective treatment of a patient with POMC deficiency, suffering from severe obesity and hyperphagia, due to administration of MC4R receptor agonist.
50 cl, 3 dwg, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIGANDS OF MELANOCORTIN RECEPTORS | 2006 |
|
RU2401841C2 |
| APPLICATION OF MELANOCORTIN FOR TREATING INSULIN SENSITIVITY | 2008 |
|
RU2453328C2 |
| MELANOCORTIN RECEPTOR LIGANDS | 2006 |
|
RU2380372C2 |
| MELANOCORTIN RECEPTOR LIGANDS | 2006 |
|
RU2439079C2 |
| PEPTIDE COMPOSITIONS | 2014 |
|
RU2725150C2 |
| HYDANTOIN MODIFIED MELANOCORTIN RECEPTOR LIGANDS | 2008 |
|
RU2450017C2 |
| ALPHA- AND GAMMA-MSH ANALOGUES | 2013 |
|
RU2668791C2 |
| METHOD (VERSIONS) AND PREPARATION FOR MODIFICATION OF EATING BEHAVIOUR | 2002 |
|
RU2519748C2 |
| PRODRUG COMPOSITIONS WITH HIGH DEGREE OF PENETRATION BASED ON PEPTIDES AND RELATED COMPOUNDS | 2010 |
|
RU2627065C2 |
| PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2690377C2 |
